Covid-19 treatment: Hetero launches remdesivir’s generic version, ‘Covifor’

Our Bureau Hyderabad | Updated on June 21, 2020 Published on June 21, 2020

Hetero has received manufacturing and marketing approval for the investigational antiviral medicine remdesivir from the Drug Controller General of India (DCGI) for the treatment of Covid-19.

It is launching the generic version of remdesivir under the ‘Covifor’ brand in India.

“Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country,” said Hetero Chairman B Partha Saradhi Reddy in a release issued here on Sunday.

“We are prepared for ensuring enough stocks required to cater to the present needs. We will continue to work closely with the government and medical community to make a difference in the fight against Covid-19,” he added.

The product is made indigenously in line with the ‘Make in India’ campaign, he added.

Remdesivir has been granted approval by the DCGI for the treatment of suspected or laboratory-confirmed cases of Covid-19 in adults and children hospitalised with severe symptoms of the disease.

Covifor will be available in 100 mg vials (injectable) which have to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner.

The product is launched under a licensing agreement with Gilead Sciences Inc to expand access to Covid-19 treatment in low and middle-income countries.

Published on June 21, 2020
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.